Jade Biosciences Inc JBIO

Morningstar Rating
$15.40 +0.07 (0.42%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

JBIO is trading at a LOCK|R^wwd premium.
Price
$15.40
Fair Value
LOCK|.vh$#BVV
Uncertainty
LOCK|k> DGzy
1-Star Price
LOCK|.nJ>h?L
5-Star Price
LOCK|.>kj@<#
Economic Moat
LOCK|$P#
Capital Allocation
—

News

Trading Information

Previous Close Price
$15.34
Day Range
$14.60–16.31
52-Week Range
$11.02–28.00
Bid/Ask
$13.50 / $16.88
Shares Outstanding
69.19M
Market Cap
$1.07B
Volume/Avg
2M / 892,214

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
—
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
—
Total Number of Employees
55

Valuation

Metric
JBIO
Price/Earnings (Normalized)
—
Price/Book Value
2.27
Price/Sales
—
Price/Cash Flow
—
Price/Earnings
No chart available

Financial Strength

Metric
JBIO
Quick Ratio
15.70
Current Ratio
16.03
Interest Coverage
—
Quick Ratio
JBIO

Profitability

Metric
JBIO
Return on Assets (Normalized)
−36.94%
Return on Equity (Normalized)
−39.69%
Return on Invested Capital (Normalized)
−42.67%
Return on Assets
JBIO

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|$wLrT@LOCK|?$j@^$135B
Regeneron Pharmaceuticals Inc
REGN
LOCK|#DT?GrLOCK|@!G@>$99B
Moderna Inc
MRNA
LOCK|%t&t?x&LOCK|B@l$84B
argenx SE ADR
ARGX
LOCK|Qk#NDw>LOCK|m>$59B
BeOne Medicines Ltd ADR
ONC
LOCK|#^s!<LLOCK|zq$48B
Royalty Pharma PLC Class A
RPRX
LOCK|&JC&!ZVLOCK|HD^!v$31B
Incyte Corp
INCY
LOCK|jqKxl$&LOCK|rG!$24B
BioNTech SE ADR
BNTX
LOCK|dv^^%kLOCK|mnv$21B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|Q<&@&?kLOCK|>ctb%$21B
Jazz Pharmaceuticals PLC
JAZZ
LOCK|!#>$?$$LOCK|xz$15B

Sponsor Center